Finlab AG
XETRA:A7A
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Finlab AG
Finlab AG
Cash Equivalents
Finlab AG
Cash Equivalents Peer Comparison
MLP
MUX
DBAN
DWS
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Finlab AG
XETRA:A7A
|
Cash Equivalents
€2.7m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
MLP SE
XETRA:MLP
|
Cash Equivalents
€1.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
19%
|
CAGR 10-Years
42%
|
|
|
Mutares SE & Co KgaA
XETRA:MUX
|
Cash Equivalents
€520.2m
|
CAGR 3-Years
53%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Deutsche Beteiligungs AG
XETRA:DBAN
|
Cash Equivalents
€32.5m
|
CAGR 3-Years
36%
|
CAGR 5-Years
14%
|
CAGR 10-Years
2%
|
|
|
DWS Group GmbH & Co KgaA
XETRA:DWS
|
Cash Equivalents
€1.4B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
A
|
AURELIUS Equity Opportunities SE & Co KgaA
XETRA:AR4
|
Cash Equivalents
€304.5m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
See Also
What is Finlab AG's Cash Equivalents?
Cash Equivalents
2.7m
EUR
Based on the financial report for Dec 31, 2022, Finlab AG's Cash Equivalents amounts to 2.7m EUR.
What is Finlab AG's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-8%
Over the last year, the Cash Equivalents growth was -68%. The average annual Cash Equivalents growth rates for Finlab AG have been -26% over the past three years , -8% over the past five years .
You don't have any saved screeners yet
